Skip to main content

Table 4 Differences in use of chemotherapy and endocrine therapy (ET) among the St Gallen risk categories.

From: Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer

  Low Intermediate High
Chemotherapy without ET 349 12,429 8,007
ET without chemotherapy 4,019 9,629 671
Chemotherapy + ET 349 6,479 3,009
None or Unknown 4,407 15,697 2,653
Total 9,124 44,234 14,340